



October 16, 2025

BSE Limited

The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India

BSE Scrip Code: **544309**

National Stock Exchange of India Limited

The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India

NSE Symbol: **IKS**

Dear Sir/Ma'am,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") – Further investment in Inventurus Knowledge Solutions, Inc., a wholly owned subsidiary.

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has made a further investment of USD 10,001,605/- in Inventurus Knowledge Solutions, Inc. ("**IKS Inc**"), a wholly owned subsidiary of the Company.

The relevant disclosure as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure - I**.

Kindly take the above-mentioned information on record.

Thanking you,

Yours sincerely

For **Inventurus Knowledge Solutions Limited**

Sameer Chavan

Company Secretary and Compliance Officer

Membership No.: F7211

Enclosure: As above

M/s. Inventurus Knowledge Solutions Limited

801, Building No. 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Airoli, Navi Mumbai - 400 708,
Thane, Maharashtra, India. | Board: +91 22 3071 1100 | Fax: 91 22 6646 6879 | info@ikshealth.in | www.ikshealth.com

ANNEXURE – I

**DISCLOSURE UNDER REGULATION 30 OF THE SEBI LODR REGULATIONS READ WITH SEBI MASTER
CIRCULAR NO. SEBI/HO/CFD/POD2/CIR/P/0155 DATED NOVEMBER 11, 2024**

Sr. No.	Particulars	Details								
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Inventurus Knowledge Solutions Inc. (“IKS Inc.”) is a wholly owned subsidiary of the Company.</p> <p>IKS Inc. is engaged in providing a care enablement platform which comprises of technology-enabled solutions for healthcare providers .</p> <p>Financial Details of IKS Inc:</p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>Amt in INR Mn FY 2024-25</th> </tr> </thead> <tbody> <tr> <td>Revenue from Operations</td> <td>6,941.11</td> </tr> <tr> <td>Other Income</td> <td>55.81</td> </tr> <tr> <td>Total Income</td> <td>6,996.92</td> </tr> </tbody> </table>	Particulars	Amt in INR Mn FY 2024-25	Revenue from Operations	6,941.11	Other Income	55.81	Total Income	6,996.92
Particulars	Amt in INR Mn FY 2024-25									
Revenue from Operations	6,941.11									
Other Income	55.81									
Total Income	6,996.92									
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length"</p>	<p>IKS Inc is a wholly owned subsidiary of the Company and therefore related party, and a transaction is on an arm's length basis.</p> <p>None of the Company's promoter / promoter group / group companies have any interest in the said transaction.</p>								
3.	Industry to which the entity being acquired belongs	<p>This is a further investment.</p> <p>Care enablement platform which comprises of technology enabled solutions for healthcare providers.</p>								
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Working Capital								

5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable								
6.	Indicative time period for completion of the acquisition	This is a further investment. On or before October 31, 2025.								
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration								
8.	Cost of acquisition or the price at which the shares are acquired	USD 643.19 per share								
9.	Percentage of shareholding / control acquired and / or number of shares acquired.	No. of equity shares acquired: 15,550/- IKS Inc is a wholly owned subsidiary of the Company and with the aforesaid investment, the shareholding percentage of the Company in IKS Inc remains the same.								
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>IKS Inc. was incorporated on September 19, 2006 under the laws of the State of Delaware, USA.</p> <p>IKS Inc. is engaged in the business of assisting U.S. based healthcare service providers deliver better, safer, and more efficient care using a combination of outsourcing and technology. It has its principal place of business in the U.S.</p> <p style="text-align: right;"><i>Amt in INR Mn</i></p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>FY 2024-25</th> <th>FY 2023-24</th> <th>FY 2022-23</th> </tr> </thead> <tbody> <tr> <td>Revenue from operations</td> <td>6,941.11</td> <td>7,027.85</td> <td>6,054.66</td> </tr> </tbody> </table>	Particulars	FY 2024-25	FY 2023-24	FY 2022-23	Revenue from operations	6,941.11	7,027.85	6,054.66
Particulars	FY 2024-25	FY 2023-24	FY 2022-23							
Revenue from operations	6,941.11	7,027.85	6,054.66							